Digitalis for treatment of congestive heart failure in patients in sinus rhythm: a systematic review and meta-analysis.

[1]  M. Pfeffer,et al.  Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme , 2003, The Lancet.

[2]  Harlan M Krumholz,et al.  Association of serum digoxin concentration and outcomes in patients with heart failure. , 2003, JAMA.

[3]  Harlan M Krumholz,et al.  Sex-based differences in the effect of digoxin for the treatment of heart failure. , 2002, The New England journal of medicine.

[4]  J. H. Patterson,et al.  Clinical benefits of low serum digoxin concentrations in heart failure. , 2002, Journal of the American College of Cardiology.

[5]  D. V. Veldhuisen.  Low-dose digoxin in patients with heart failure : Less toxic and at least as effective? , 2002 .

[6]  C. O'connor,et al.  Does digitalis influence the response to beta-blockade in patients with severe chronic heart failure? Results of the COPERNICUS study , 2002 .

[7]  J. Cohn,et al.  A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. , 2001, The New England journal of medicine.

[8]  S. Yusuf,et al.  Effect of age on mortality, hospitalizations and response to digoxin in patients with heart failure: the DIG study. , 2001, Journal of the American College of Cardiology.

[9]  D. DeMets,et al.  Effect of carvedilol on survival in severe chronic heart failure. , 2001, The New England journal of medicine.

[10]  B. Pitt,et al.  The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure , 2000 .

[11]  B. Pitt,et al.  The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. , 1999, The New England journal of medicine.

[12]  Fach,et al.  Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in-Congestive Heart Failure (MERIT-HF) , 1999, The Lancet.

[13]  D. Levy,et al.  Congestive heart failure in subjects with normal versus reduced left ventricular ejection fraction: prevalence and mortality in a population-based cohort. , 1999, Journal of the American College of Cardiology.

[14]  R. Kelly,et al.  Cardiac glycosides in the next millennium. , 1999, Progress in cardiovascular diseases.

[15]  Thomas D. Giles,et al.  Consensus recommendations for the management of chronic heart failure: Introduction , 1999 .

[16]  CIBIS-II Investigators and Committees.  The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial , 1999, The Lancet.

[17]  Marvin A. Konstam,et al.  Heart Failure Society of America (HFSA) practice guidelines. HFSA guidelines for management of patients with heart failure caused by left ventricular systolic dysfunction--pharmacological approaches. , 1999, Journal of cardiac failure.

[18]  D. DeMets,et al.  A Dose-Dependent Increase in Mortality with Vesnarinone among Patients with Severe Heart Failure , 1998 .

[19]  M. Gheorghiade,et al.  Clinical predictors of worsening heart failure during withdrawal from digoxin therapy. , 1998, American heart journal.

[20]  J. Feinglass,et al.  Systolic function, readmission rates, and survival among consecutively hospitalized patients with congestive heart failure. , 1997, American heart journal.

[21]  P. Grayburn,et al.  Does digoxin provide additional hemodynamic and autonomic benefit at higher doses in patients with mild to moderate heart failure and normal sinus rhythm? , 1997, Journal of the American College of Cardiology.

[22]  E. J. Brown,et al.  The effect of digoxin on mortality and morbidity in patients with heart failure. , 1997, The New England journal of medicine.

[23]  Cindy Farquhar,et al.  3 The Cochrane Library , 1996 .

[24]  J. Cohn,et al.  The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. , 1996, The New England journal of medicine.

[25]  M. Gheorghiade,et al.  Economic outcomes of withdrawal of digoxin therapy in adult patients with stable congestive heart failure. , 1995, Journal of the American College of Cardiology.

[26]  A. Skene,et al.  Treatment of severe heart failure: quantity or quality of life? A trial of enoximone. Enoximone Investigators. , 1994, British heart journal.

[27]  W. Gaasch.  Diagnosis and treatment of heart failure based on left ventricular systolic or diastolic dysfunction. , 1994, JAMA.

[28]  D. D. Bono.  Digoxin in eurhythmic heart failure: PROVED or "not proven"? , 1994, The Lancet.

[29]  M. Gheorghiade,et al.  WITHDRAWAL OF DIGOXIN FROM PATIENTS WITH CHRONIC HEART FAILURE TREATED WITH ANGIOTENSIN CONVERTING ENZYME INHIBITORS , 2010 .

[30]  J. Brouwer,et al.  Double-blind placebo-controlled study of ibopamine and digoxin in patients with mild to moderate heart failure: results of the Dutch Ibopamine Multicenter Trial (DIMT). , 1993, Journal of the American College of Cardiology.

[31]  B. Uretsky,et al.  Randomized study assessing the effect of digoxin withdrawal in patients with mild to moderate chronic congestive heart failure: results of the PROVED trial. PROVED Investigative Group. , 1993, Journal of the American College of Cardiology.

[32]  M. Packer.  The neurohormonal hypothesis: a theory to explain the mechanism of disease progression in heart failure. , 1992, Journal of the American College of Cardiology.

[33]  D. DeMets,et al.  Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group. , 1991, The New England journal of medicine.

[34]  D. Ferguson,et al.  Digoxin. A neurohormonal modulator in heart failure? , 1991, Circulation.

[35]  Salim Yusuf,et al.  Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. , 1991, The New England journal of medicine.

[36]  R. Mayou,et al.  Exercise capacity and quality of life in the treatment of heart failure , 1990, Clinical pharmacology and therapeutics.

[37]  G. Guyatt,et al.  To what extent do congestive heart failure patients in sinus rhythm benefit from digoxin therapy? A systematic overview and meta-analysis. , 1990, The American journal of medicine.

[38]  D. Ferguson,et al.  Sympathoinhibitory responses to digitalis glycosides in heart failure patients. Direct evidence from sympathetic neural recordings. , 1989, Circulation.

[39]  J. Aronson,et al.  Clinical, haemodynamic, and pharmacological effects of withdrawal and reintroduction of digoxin in patients with heart failure in sinus rhythm after long term treatment. , 1989, British heart journal.

[40]  R. Schlant,et al.  A comparison of oral milrinone, digoxin, and their combination in the treatment of patients with chronic heart failure. , 1989, The New England journal of medicine.

[41]  T. A. S. Group,et al.  DOUBLE-BLIND PLACEBO-CONTROLLED COMPARISON OF DIGOXIN AND XAMOTEROL IN CHRONIC HEART FAILURE , 1988, The Lancet.

[42]  G. Guyatt,et al.  A controlled trial of digoxin in congestive heart failure. , 1988, The American journal of cardiology.

[43]  M. Wilén,et al.  Comparative effects of therapy with captopril and digoxin in patients with mild to moderate heart failure. The Captopril-Digoxin Multicenter Research Group. , 1988, JAMA.

[44]  K. Swedberg,et al.  Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). , 1988, The American journal of cardiology.

[45]  R. Byington,et al.  Association of digitalis therapy with mortality in survivors of acute myocardial infarction: observations in the Beta-Blocker Heart Attack Trial. , 1985, Journal of the American College of Cardiology.

[46]  J. Fleiss,et al.  Effect of digitalis treatment on survival after acute myocardial infarction. , 1985, The American journal of cardiology.

[47]  R. Cody,et al.  Suppression of the renin-angiotensin system by intravenous digoxin in chronic congestive heart failure. , 1983, The American journal of medicine.

[48]  M. Gheorghiade,et al.  Effects of discontinuing maintenance digoxin therapy in patients with ischemic heart disease and congestive heart failure in sinus rhythm. , 1983, The American journal of cardiology.

[49]  G. D. Johnston,et al.  Digoxin Withdrawal After Cardiac Failure in Patients with Sinus Rhythm , 1983, Journal of cardiovascular pharmacology.

[50]  J. Fleg,et al.  Is digoxin really important in treatment of compensated heart failure? A placebo-controlled crossover study in patients with sinus rhythm. , 1982, The American journal of medicine.

[51]  R. A. Johnson,et al.  Heart failure in outpatients: a randomized trial of digoxin versus placebo. , 1982, The New England journal of medicine.

[52]  A. Moss,et al.  Digitalis‐associated Cardiac Mortality After Myocardial Infarction , 1981, Circulation.

[53]  G. D. Johnston,et al.  IS MAINTENANCE DIGOXIN NECESSARY IN PATIENTS WITH SINUS RHYTHM? , 1979, The Lancet.

[54]  A. Guz,et al.  The clinical value of digoxin in patients with heart failure and sinus rhythm. , 1978, The Quarterly journal of medicine.

[55]  S. Hull,et al.  DISCONTINUATION OF MAINTENANCE DIGOXIN THERAPY IN GENERAL PRACTICE , 1977, The Lancet.

[56]  R. Dobbs,et al.  Maintenance digoxin after an episode of heart failure: placebo-controlled trial in outpatients. , 1977, British medical journal.

[57]  C. Oakley,et al.  The functional defect in amyloid heart disease. The "stiff heart" syndrome. , 1975, The American journal of cardiology.

[58]  G. MacGregor,et al.  Diuretic-induced oedema. , 1975, Lancet.

[59]  J. Kelly,et al.  The Efficacy of Digitalis Withdrawal in an Institutional Aged Population , 1974, Journal of the American Geriatrics Society.

[60]  M. Manku,et al.  Letter: Aspirin and arteriolar responses to noradrenaline. , 1974, Lancet.

[61]  J. Dall.  Maintenance Digoxin in Elderly Patients , 1970, British medical journal.

[62]  I. Starr,et al.  Blind study on the action of digitoxin on elderly women. , 1969, American heart journal.